Posted in | Nanomedicine

Novavax Provides Latest Data from NHP Ebola Challenge at International Symposium on Filoviruses

Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Gale Smith, Ph.D., Vice President, Vaccine Development, will present, "Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells," at the 7th International Symposium on Filoviruses, Saturday, March 28, 2015 at 10:15 a.m. at the Washington Marriott Metro Center in Washington, D.C.

As part of his talk, Dr. Smith will present new data from a second non-human primate (NHP) study which was conducted by the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases (NIH-NIAID-DMID). In that study, animals received two injections of a 5µg dose of Novavax' Ebola GP Vaccine together with its proprietary Matrix-M adjuvant and were then challenged with a lethal dose of the Ebola virus. Similar to the previous NHP study, the challenge was lethal for the control animals, whereas the animals immunized with Novavax' EBOV GP Vaccine remain healthy 18 days post challenge.

"This data provides significant, independent confirmation that our Ebola GP Vaccine is safe and effective in providing protection in NHP models," said Dr. Smith. "Our vaccine is the first subunit Ebola GP-based vaccine to provide protection in non-human primates and this confirmatory data strongly supports the advancement of this program. Importantly, although we developed our Ebola GP Vaccine from the Makona strain, which is the strain responsible for the recent Ebola epidemic in West Africa, these primates were challenged with the Kikwit strain of Ebola, which suggests that our vaccine candidate may be protective across different variants of the virus."

Novavax is currently conducting a Phase 1 clinical trial of its Ebola GP Vaccine in healthy subjects. It expects top-line data from this trial in mid-2015.

Source: http://www.novavax.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Novavax Inc.. (2019, February 11). Novavax Provides Latest Data from NHP Ebola Challenge at International Symposium on Filoviruses. AZoNano. Retrieved on November 22, 2019 from https://www.azonano.com/news.aspx?newsID=32437.

  • MLA

    Novavax Inc.. "Novavax Provides Latest Data from NHP Ebola Challenge at International Symposium on Filoviruses". AZoNano. 22 November 2019. <https://www.azonano.com/news.aspx?newsID=32437>.

  • Chicago

    Novavax Inc.. "Novavax Provides Latest Data from NHP Ebola Challenge at International Symposium on Filoviruses". AZoNano. https://www.azonano.com/news.aspx?newsID=32437. (accessed November 22, 2019).

  • Harvard

    Novavax Inc.. 2019. Novavax Provides Latest Data from NHP Ebola Challenge at International Symposium on Filoviruses. AZoNano, viewed 22 November 2019, https://www.azonano.com/news.aspx?newsID=32437.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit